Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Cramer remains steadfast on Eli Lilly and Company (NYSE:LLY) as per Mad Money’s episode on September 30. Despite there being ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

In 1988, Oprah pulled a wagon with 67 pounds of fat, showcasing her weight loss. Fans now wonder if she'll consider GLP-1 for control.

A new study published in the journal JAMA Network Open found that food left in the stomach or stool left in the bowel can ...

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...